Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
Add more filters










Publication year range
3.
Arch Dis Child Educ Pract Ed ; 106(3): 152-154, 2021 06.
Article in English | MEDLINE | ID: mdl-31506322

ABSTRACT

A preterm baby boy was born in good condition at 31+5 weeks gestation with a birth weight of 1956 g, following a precipitous labour with no prolonged rupture of membranes and no opportunity for administration of antenatal steroids to mother. Following admission to the neonatal unit, he developed respiratory distress and was commenced on nasal continuous positive airway pressure (CPAP) of 6 cm of water. At 24 hours of age, he developed a left-sided tension pneumothorax (figure 1), requiring endotracheal intubation and insertion of a chest drain. He received two doses of surfactant and was extubated onto CPAP on day 3. There was reaccumulation of the pneumothorax on day 4, which was subsequently drained. He remained self-ventilating in air in the second week of life. From day 15 to day 30, he required humidified high flow nasal cannula oxygen (fractional inspired oxygen up to 0.4), in view of marked subcostal and intercostal recession, intolerance to handling and a compensated respiratory acidosis on capillary blood gases. Figure 2 is the chest radiograph undertaken in the third week of life.


Subject(s)
Pneumothorax , Respiratory Distress Syndrome, Newborn , Female , Humans , Infant, Newborn , Infant, Premature , Male , Pneumothorax/diagnosis , Pneumothorax/therapy , Pregnancy , Pulmonary Emphysema , Respiratory Distress Syndrome, Newborn/diagnosis , Respiratory Distress Syndrome, Newborn/etiology , Respiratory Distress Syndrome, Newborn/therapy
10.
J Nerv Ment Dis ; 202(11): 822-8, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25259948

ABSTRACT

The current study sought to evaluate the validity and reliability of a brief measure of overall functioning for adolescents. Clinicians were asked to complete the Overall Functioning Scale (OFS) for 72 adolescents consecutively admitted to the adolescent psychiatric inpatient service of a community safety net medical center. The results revealed that this new measure is related to the patients' length of stay, clinician-rated measures of social cognition and object relations, Global Assessment of Functioning (GAF) score at admission, as well as global rating of engagement in individual psychotherapy. The results also showed that the OFS was related to the patients' history of nonsuicidal self-harm as well as treatment outcome as assessed by measures of psychological health and well-being as well as symptoms. Hierarchical regressions reveal that the OFS shows incremental validity greater than the admission GAF score in predicting length of stay. The results also showed that the OFS demonstrates interrater reliability in the excellent range (intraclass correlation coefficient(1,2)) of 0.88. Clinical implications of the use of this tool and areas of future research are discussed.


Subject(s)
Adolescent Behavior/psychology , Inpatients/psychology , Psychiatric Department, Hospital/standards , Psychiatric Status Rating Scales/standards , Adolescent , Adult , Female , Humans , Male , Psychiatric Department, Hospital/trends , Reproducibility of Results
14.
Proc Natl Acad Sci U S A ; 103(19): 7444-9, 2006 May 09.
Article in English | MEDLINE | ID: mdl-16651519

ABSTRACT

Targeted cancer therapies exploit the continued dependence of cancer cells on oncogenic mutations. Such agents can have remarkable activity against some cancers, although antitumor responses are often heterogeneous, and resistance remains a clinical problem. To gain insight into factors that influence the action of a prototypical targeted drug, we studied the action of imatinib (STI-571, Gleevec) against murine cells and leukemias expressing BCR-ABL, an imatinib target and the initiating oncogene for human chronic myelogenous leukemia (CML). We show that the tumor suppressor p53 is selectively activated by imatinib in BCR-ABL-expressing cells as a result of BCR-ABL kinase inhibition. Inactivation of p53, which can accompany disease progression in human CML, impedes the response to imatinib in vitro and in vivo without preventing BCR-ABL kinase inhibition. Concordantly, p53 mutations are associated with progression to imatinib resistance in some human CMLs. Our results identify p53 as a determinant of the response to oncogene inhibition and suggest one way in which resistance to targeted therapy can emerge during the course of tumor evolution.


Subject(s)
Fusion Proteins, bcr-abl/metabolism , Leukemia/metabolism , Leukemia/pathology , Tumor Suppressor Protein p53/metabolism , Animals , Benzamides , Cell Line, Tumor , Disease Progression , Drug Resistance, Neoplasm/genetics , Hematopoietic Stem Cell Transplantation , Humans , Imatinib Mesylate , Leukemia/drug therapy , Leukemia/genetics , Mice , Mice, Knockout , Mutation/genetics , Neoplasm Transplantation , Piperazines/pharmacology , Pyrimidines/pharmacology , Survival Rate , Tumor Suppressor Protein p53/deficiency , Tumor Suppressor Protein p53/genetics
15.
J Invest Dermatol ; 125(2): 294-306, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16098040

ABSTRACT

Diseased skin often exhibits a deregulated program of the keratinocyte maturation necessary for epidermal stratification and function. Protein kinase D (PKD), a serine/threonine kinase, is expressed in proliferating keratinocytes, and PKD activation occurs in response to mitogen stimulation in other cell types. We have proposed that PKD functions as a pro-proliferative and/or anti-differentiative signal in keratinocytes and hypothesized that differentiation inducers will downmodulate PKD to allow differentiation to proceed. Thus, changes in PKD levels, autophosphorylation, and activity were analyzed upon stimulation of differentiation and proliferation in primary mouse keratinocytes. Elevated extracellular calcium and acute 12-O-tetradecanoylphorbol-13-acetate (TPA) treatments induced differentiation and triggered a downmodulation of PKD levels, autophosphorylation at serine 916, and activity. Chronic TPA treatment stimulated proliferation and resulted in a recovery of PKD levels, autophosphorylation, and activity. Immunohistochemical analysis demonstrated PKD localization predominantly in the proliferative basal layer of mouse epidermis. Co-expression studies revealed a pro-proliferative, anti-differentiative effect of PKD on keratinocyte maturation as monitored by increased and decreased promoter activities of keratin 5, a proliferative marker, and involucrin, a differentiative marker, respectively. This work describes the inverse regulation of PKD during keratinocyte differentiation and proliferation and the pro-proliferative/anti-differentiative effects of PKD co-expression on keratinocyte maturation.


Subject(s)
Keratinocytes/cytology , Keratinocytes/enzymology , Protein Kinase C/metabolism , Animals , Animals, Newborn , Antibody Specificity , COS Cells , Calcitriol/pharmacology , Calcium/pharmacology , Calcium Channel Agonists/pharmacology , Carcinogens/pharmacology , Cell Differentiation/physiology , Cell Division/physiology , Chlorocebus aethiops , Extracellular Space/drug effects , Keratin-15 , Keratin-5 , Keratinocytes/drug effects , Keratins/genetics , Mice , Mice, Inbred ICR , Phosphorylation , Promoter Regions, Genetic/physiology , Protein Kinase C/genetics , Protein Kinase C/immunology , Protein Precursors/genetics , Tetradecanoylphorbol Acetate/pharmacology , Transglutaminases/metabolism
16.
Nature ; 428(6980): 332-7, 2004 Mar 18.
Article in English | MEDLINE | ID: mdl-15029198

ABSTRACT

Evading apoptosis is considered to be a hallmark of cancer, because mutations in apoptotic regulators invariably accompany tumorigenesis. Many chemotherapeutic agents induce apoptosis, and so disruption of apoptosis during tumour evolution can promote drug resistance. For example, Akt is an apoptotic regulator that is activated in many cancers and may promote drug resistance in vitro. Nevertheless, how Akt disables apoptosis and its contribution to clinical drug resistance are unclear. Using a murine lymphoma model, we show that Akt promotes tumorigenesis and drug resistance by disrupting apoptosis, and that disruption of Akt signalling using the mTOR inhibitor rapamycin reverses chemoresistance in lymphomas expressing Akt, but not in those with other apoptotic defects. eIF4E, a translational regulator that acts downstream of Akt and mTOR, recapitulates Akt's action in tumorigenesis and drug resistance, but is unable to confer sensitivity to rapamycin and chemotherapy. These results establish Akt signalling through mTOR and eIF4E as an important mechanism of oncogenesis and drug resistance in vivo, and reveal how targeting apoptotic programmes can restore drug sensitivity in a genotype-dependent manner.


Subject(s)
Apoptosis , Drug Resistance, Neoplasm , Eukaryotic Initiation Factor-4E/metabolism , Lymphoma, B-Cell/drug therapy , Lymphoma, B-Cell/pathology , Protein Serine-Threonine Kinases , Proto-Oncogene Proteins/metabolism , Signal Transduction , Animals , Antibiotics, Antineoplastic/pharmacology , Antibiotics, Antineoplastic/therapeutic use , Apoptosis/drug effects , Cell Division/drug effects , Cell Survival/drug effects , Disease Progression , Eukaryotic Initiation Factor-4E/genetics , Eukaryotic Initiation Factor-4G/metabolism , Female , Lymphoma, B-Cell/metabolism , Mice , Mice, Inbred C57BL , Neoplasm Transplantation , Protein Kinase Inhibitors , Protein Kinases/metabolism , Proto-Oncogene Proteins/antagonists & inhibitors , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins c-akt , Proto-Oncogene Proteins c-bcl-2/metabolism , Signal Transduction/drug effects , Sirolimus/pharmacology , Sirolimus/therapeutic use , TOR Serine-Threonine Kinases , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism
17.
Biochim Biophys Acta ; 1643(1-3): 25-36, 2003 Dec 07.
Article in English | MEDLINE | ID: mdl-14654225

ABSTRACT

The major component of the epidermis, keratinocytes, must continuously proliferate and differentiate to form the mechanical and water permeability barrier of the skin. Our previous data have suggested a potential role in these processes for phospholipase D (PLD), an enzyme that hydrolyzes phospholipids to generate phosphatidic acid. In the presence of primary alcohols, PLD also catalyzes a transphosphatidylation reaction to produce phosphatidylalcohols, and this characteristic has been exploited to monitor the activity of PLD in intact cells. In this report, PLD was demonstrated to utilize the physiological alcohol glycerol to form phosphatidylglycerol (PG) in vitro. In intact primary murine epidermal keratinocytes treated for 24 h with elevated extracellular Ca(2+) levels, but not 1,25-dihydroxyvitamin D(3), incubation with radioactive glycerol resulted in an increase in PLD-mediated radiolabeled PG production. This effect was dose-dependent and biphasic, with maximal PG formation detected after exposure to an intermediate (125 microM) Ca(2+) concentration. Furthermore, the biphasic nature of the response was due, in part, to a corresponding biphasic change in glycerol uptake. Finally, short-term treatment of keratinocytes with phorbol 12-myristate 13-acetate (PMA) failed to increase PG synthesis and inhibited glycerol uptake. Since (1) PMA is reported to activate PLD-1 to a greater extent than PLD-2, (2) 1,25-dihydroxyvitamin D(3) increases the expression/activity of PLD-1 in keratinocytes, and (3) PLD-2 is co-localized with a glycerol channel in keratinocyte membrane microdomains, we speculate that radiolabeled PG production from radioactive glycerol is a measure of PLD-2 activation in these cells. Our results also suggest that PLD-mediated PG synthesis may be regulated at the level of both PLD activity and alcohol substrate availability via changes in glycerol uptake.


Subject(s)
Keratinocytes/drug effects , Keratinocytes/metabolism , Phosphatidylglycerols/biosynthesis , Phospholipase D/metabolism , Animals , Calcitriol/pharmacology , Calcium/pharmacology , Cell Differentiation/drug effects , Cells, Cultured , Epidermal Cells , Glycerol/metabolism , Keratinocytes/enzymology , Mice , Tetradecanoylphorbol Acetate/pharmacology
18.
J Pharmacol Exp Ther ; 302(1): 352-8, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12065737

ABSTRACT

Much data in the literature suggest a role for protein kinase C (PKC) in regulating keratinocyte proliferation and differentiation. Nevertheless, the exact role of this family of isoenzymes is unclear, since PKC agonists (e.g., phorbol esters) are known to stimulate expression of both proliferative and differentiative markers in keratinocytes. Similarly, PKC inhibitors have been demonstrated both to inhibit [2-[1-3(aminopropyl)indol-3-yl]-3(1-methyl-1H-indol-3-yl)maleimide, acetate (Ro 31-7549) and 3-[1-[3-(amidinothio)propyl-1H-indol-3-(1-methyl-1H-indol-3yl) maleimide (Ro 31-8220)] and to induce (staurosporine) keratinocyte differentiation. In this study, we examined the role of the PKC inhibitor, Gödecke 6976 (Gö6976) [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo (3,4-c)-carbazole], on keratinocyte proliferation, as measured by DNA synthesis, and differentiation, as monitored by transglutaminase activity. This compound is reported to be selective for the conventional PKC isoforms, of which keratinocytes express only PKCalpha, and for protein kinase D (PKD; also known as PKCmu). We report that Gö6976 stimulated transglutaminase activity. Consistent with this effect, Gö6976 also potently inhibited [(3)H]thymidine incorporation (a half-maximal inhibitory concentration of approximately 0.1 microM). In addition, Gö6976 (1 microM) was able to enhance the stimulation of transglutaminase activity by 1,25-dihydroxyvitamin D(3) but had no effect on D(3)-induced expression of keratin-1. Conversely, Gö6983 [2-[1-(3-dimethylaminopropy)-5-methoxyindol-3-yl]-3-(1H-indol-3-yl)maleimide], a similar compound that also selectively inhibits conventional PKCalpha, but not PKD, had little or no effect on DNA synthesis or transglutaminase activity (up to 1 microM). The effect of Gö6976 was not due to cytotoxicity as its effect on thymidine incorporation was largely reversible, and its stimulation of transglutaminase activity could be inhibited by another general PKC inhibitor, bisindolylmaleimide I. Therefore, our results suggest a proproliferative, antidifferentiative role for PKD in epidermal maturation.


Subject(s)
Carbazoles/pharmacology , Enzyme Inhibitors/pharmacology , Keratinocytes/enzymology , Protein Kinase C/antagonists & inhibitors , Transglutaminases/biosynthesis , Animals , Blotting, Western , Cell Differentiation/drug effects , Cell Division/drug effects , DNA/biosynthesis , Epidermal Cells , Epidermis/drug effects , Keratinocytes/drug effects , Mice , Mice, Inbred ICR , Nerve Growth Factors/pharmacology , Nucleic Acid Synthesis Inhibitors/pharmacology , Receptors, Dopamine D2/drug effects , Receptors, Dopamine D3 , Stimulation, Chemical
SELECTION OF CITATIONS
SEARCH DETAIL
...